Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12782323 | 1.00 | DPP4 (0.41) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL15086350 | 1.00 | DPP4 (0.41) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL17792713 | 0.80 | NOS2 (0.33) | GRIK1ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL17322649 | 0.80 | PTGS1 (0.39) | GRIK1ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL197139 | 0.79 | SLC7A5 (0.48) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL196695 | 0.79 | SLC7A5 (0.48) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL15190002 | 0.79 | DPP4 (0.41) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL8253827 | 0.79 | DPP4 (0.41) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL15247971 | 0.79 | DPP4 (0.41) | DPP4GRIK1ALDH1A1MAPTPTGS1 | |
| SCHEMBL197117 | 0.79 | SLC7A5 (0.48) | DPP4GRIK1ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2015006100-A1 | ARYL AMIDE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | DPP4 3458/4885GRIK1 965/4885ALDH1A1 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.